FIG. 4.
Characterization of in vitro-induced HIV-specific CTL. (a) HIV-specific lysis. Naïve autologous lymphocytes were stimulated with GMDC (left) and control (right) autologous DCs. Seven days later, primed T cells were tested for HIV-specific CTL activity against autologous target macrophages (□) and macrophages pulsed with Gag (p55) protein (■). (b) Analysis of in vitro-primed HIV-1-specific CTL. Effector T cells induced by GMDC were tested against autologous target macrophages pulsed with the Gag protein (p55) (effector/target ratio, 50:1) in the presence and absence of CD8-specific antibodies (CD8AB). (c) GMDC activation of T cells specific to the dominant HLA-A*02-restricted Gag CTL epitope. GMDC derived from a naïve HLA-A*02 individual were used to prime autologous T cells. Seven days later the primed T cells were restimulated overnight with either autologous B-LCL cells (left) or B-LCL cells pulsed with HLA-A∗02-restricted p17 Gag77–85 (SLYNTVATL) peptide (right).